235 filings
Page 9 of 12
8-K
yh1yp 3c5yoe4dk6
24 Oct 17
ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431
12:00am
8-K
bc4p2s2z74m
19 Oct 17
Other Events
12:00am
8-K
iyce9vhz
17 Oct 17
ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology
12:00am
8-K
7j7by1hlkk0 hts
3 Oct 17
ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017
12:00am
8-K
3vxql1idz x1lfb58553
11 Sep 17
ContraVir Pharmaceuticals Receives HBV
12:00am
8-K
0dj3zjmr
3 Aug 17
ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at Upcoming AASLD Meeting® 2017
12:00am
8-K
7m7o 6vsomuw81
9 Jun 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
rz07eluqywh8l
26 May 17
Departure of Directors or Certain Officers
12:00am
8-K
ufwjnn9
4 May 17
Other Events
12:00am
8-K
c3p2wfynoks r48
2 May 17
Contravir Pharmaceuticals Announces Closing of Public Offering of Common Stock and Warrants
12:00am
8-K
gigsvosi psi2wtm3
25 Apr 17
ContraVir Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
12:00am
8-K
n4xx2z7 pi
24 Apr 17
Data Enhances Understanding of ContraVir’s Complementary Anti-HBV
12:00am
8-K
8nioy5
20 Apr 17
Oral Presentation at EASL Highlights ContraVir’s Tenofovir Exalidex (TXL™) Antiviral Activity in Hepatitis B (HBV) Patients
12:00am
8-K
94lobyms444tevdbzq
4 Apr 17
Other Events
12:00am
8-K
81v45p1p g71n
4 Jan 17
ContraVir Pharmaceuticals to Present at Biotech Showcase 2017
12:00am
8-K
jllfw6a
3 Jan 17
ContraVir Awarded Grant from Canada’s National Research Council to Advance CRV431 for the Treatment of Hepatitis B
12:00am
8-K
2kd 448wd6k
19 Dec 16
Other Events
12:00am
8-K
x1uy1kk5jy
15 Dec 16
ContraVir Appoints Business Development Executive Tamar Howson to its Board of Directors
12:00am
8-K
pjvvbn
9 Dec 16
Other Events
12:00am
8-K
s4lrms8pgacl
7 Nov 16
ContraVir to Present at AASLD’s The Liver Meeting® 2016
12:00am